Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5861168A · kind A · utility
71Cited by
15References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 1996 |
| Grant date | Jan 19, 1999 |
| Priority date | — |
| Expiry date | Dec 16, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K48/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Vessels suffering vascular injury from angioplasty are treated with L-arginine intramurally. The incidents associated with restenosis are substantially reduced providing for a reduced incidence of restenosis as a result of the injury.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.